Research Paper Volume 16, Issue 12 pp 10546—10562

Figure 5. Overexpression of NAT1 weakens the glycolysis ability of colorectal cancer cells and thus inhibits VEGF expression. (A–C) In the TCGA database, VEGFA was negatively correlated with NAT1 expression and positively correlated with the expression of glycolytic related enzymes (GLUT1, LDHA); (D, E) The glycolysis ability of colorectal cancer cells is correlated with the expression of VEGF, and glycolysis can enhance the expression of VEGF; (F) In vitro animal experiments showed that overexpression of NAT1 combined with VEGF inhibitors could better inhibit the occurrence of liver metastasis; (G, H) Overexpression of NAT1 combined with VEGF inhibitors can better reduce the expression of VEGF and CD31 in liver metastases.